

Index

Note: Page numbers of article titles are in **boldface** type.

A

AC133 antigen, 392, 395. *See also* CD133.
ACTIVATE (A Complementary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII), 463
Active immunotherapy, 362, 462–463
Adnectins, 435
Adoptive immunotherapy, 361–362, 460–462, 482–486
AEE788 (small molecule inhibitor), 408
Aflibercept, 434–435
AG490 monoclonal antibody, 384
5-Aminolevulinic acid, for fluorescence imaging, in resection, **371–377**, 441
Angiogenesis
 bevacizumab effects on, 418–423
 CD133 in, 398–399
 inhibitors of, 432–435
 STAT3 effects on, 382
Angiopoietin, bevacizumab and, 422–423
Antibody-mediated immunotherapy, 486–490
Aphasia, postoperative, 503–504
Apoptosis, 358–359
Autologous tumor cells, 462, 483
Avastin. *See* Bevacizumab.

B

BCNU, 431, 520
Bevacizumab, 410, 412, **417–427**, 488–490
 adverse reaction to, 422–423
 as radiosensitizer, 434–435
 chemotherapy and, 422
 controversy over, 418
 for recurrent glioma, 418
 molecular mechanisms of, 418–421
 radiotherapy and, 422
 resistance to, 422–423
 surgery and, 421–422
B7-H1, pathogenicity of, 358
Biologic cooperation, in radiosensitization, 430, 431
Biopsy, 499–500
Bortezomib, 412
Brachytherapy, nanoparticles for, 443
Brain, language mapping in, **497–506**

C

Cabozantinib, 435
Camptothecin, 431, 442

Cancer stem cells, 392, 395–396
Carmustine, 431, 510
CD133, **391–405**
 as stem cell marker, 392–394
 discovery of, 392
 gene for, 392
 glioma cells without, 394–398
 in angiogenesis, 398–399
 studies of, limitations of, 395
 subpopulations of, 395–398
 therapeutic potential of, 400–401
Cediranib, 410, 435
CENTRIC study, 412
Cetuximab, 383, 487
Chemotherapy
 bevacizumab effects on, 422
 for pediatric patients, 519–520
 immunosuppressive effects of, 359
 myeloablative, 520
 nanoparticles for, 443–444
 quality of life considerations on, 510–511
 resection with, 498
 small molecule inhibitors for, **407–416**
Chimeric antigen receptors, 486
Chlorotoxin, in nanoparticles, 441
Cilgenitide, 412
Ciliary neurotrophic factor, STAT3 effects on, 382
Cobalt ferrites, 442
Cognitive impairment, quality of life with, 509–510
Computed tomography, for pediatric gliomas, 517
Convection-enhanced delivery, of nanoparticles, 449
Cortical stimulation, for language mapping, 501–503
Corticosteroids, immunosuppressive effects of, 359
Cytokines
 for immunotherapy, 359–360, 463–465
 pathogenicity of, 358–359
Cytotoxic enhancement, in radiosensitization, 430
Cytotoxic T cells, 361, 460–462, 483–486

D

Dartmouth, aminolevulinic acid studies of, 373–376
Dasatinib, 409, 435
Delta-Notch pathway, bevacizumab and, 422–423
Dendritic cells, 362, 462–463
Dextran, in nanoparticles, 441
Diffusion tensor imaging tractography, 497, 500–501
Direct cortical stimulation, for language mapping, 501–503

Direct subcortical stimulation, for language mapping, 502–503
 DNA replication, inhibitors of, 431–433
 Doxorubicin, 433
 Draining lymph nodes, cytotoxic T cells from, 461
 Dynamic model, of CD133 cells, 396–397

E

Edotecarin, 411
 EGFRvIII protein, 463, 487, 520
 Electrical stimulation, for language mapping, 501–503
 Eloquent brain regions, language mapping in, **497–506**
 Encephalopathy, radiation-induced, 509–510
 Endogenous vaults, **451–458**
 Endothelial cells, tumor-derived, 398–399
 Enzastaurin, 411
 Epidermal growth factor receptor
 in pediatric patients, 516
 in vaccine preparation, 362
 inhibitors of, 408–409, 435
 Erlotinib, 383, 408–410
 Etoposide, 411, 520
 European Organization for Research and Treatment of Cancer, radiosensitizer studies of, 429–435
 Evirolimus, 411

F

F3 peptide, in nanoparticles, 441
 Fas ligand, pathogenicity of, 358
 Ferrites, in nanoparticles, 442
 Fluorescence imaging, with aminolevulinic acid, in resection, **371–377**
 Fullerene magnetic nanotubes, 441, 443

G

Gadolinium, in nanoparticles, 441
 Galectin, pathogenicity of, 358
 Gefitinib, 383, 408, 521
 Gene therapy, nanoparticles for, 442–443
 German multi-institutional trial, 372–374
 Glimatecan, 411
 Glioblastoma multiforme, CD133 and, **391–405**
 Gliomas, high-grade. *See* High-grade gliomas.
 Gliomatosis cerebri, 518
 Gold nanoparticles, 443

H

Healing, bevacizumab effects on, 423
 Heat shock proteins, in vaccine preparation, 362
 Hemorrhage, intracranial, bevacizumab and, 423
 Hierarchical model, of CD133 cells, 396

High-grade gliomas
 in pediatric patients, **515–523**
 isocitrate dehydrogenase-1 defects in, **471–480**
 language mapping for, **497–506**
 pathophysiology of, 358–359
 standard of care for, 459
 treatment of
 bevacizumab for. *See* Bevacizumab.
 CD133-related, **391–405**
 endogenous vaults for, **451–458**
 immunotherapy for, **357–370, 459–470, 481–495**
 nanotechnology for, **439–449**
 quality of life with, **507–513**
 radiosensitizers for, **429–437**
 small-molecular inhibitors for, **407–416**
 STAT3 inhibitors for, **379–389**
 surgical. *See* Surgery.
 versus low-grade gliomas, 515
 Histone deacetylases inhibitors, 412
 Hospice care, 511–512
 Human leukocyte antigens, defects of, 358
 Human lung resistance protein (untranslated vault RNA), 452–454
 Hyperthermia, nanoparticles for, 441–442

I

IDHs. *See* Isocitrate dehydrogenases.
 Imatinib, 408–410, 520
 Immunomodulation, 463–465
 Immunotherapy, **357–370, 459–470**
 active, 362, 462–463
 adoptive, 361–362, 460–462, 482–486
 antibody-mediated, 486–490
 challenges in, 465
 cytokines in, 359–360
 immunomodulation, 463–465
 multimodality, 362–363
 passive, 360–362, **481–495**
 pathologic basis of, 358–359
 serotherapy, 360–361
 strategies of, 359
 Integrin inhibitors, 412
 Interferons, therapeutic, 359, 463–464
 Interleukins, therapeutic, 359–361, 463–464
 Intracellular signaling, inhibitors of, 410–412
 Intracranial hemorrhage, bevacizumab and, 423
 Irinotecan, 411–412, 487, 489–490
 Isocitrate dehydrogenases, **471–480**
 function of, 471–472
 mutations of, 472–477
 detection of, 475–476
 genetic characteristics of, 474–475
 in non-gliomas, 476–477
 prognosis and, 475
 putative role of, 473–474

J

Janus tyrosine kinases, STAT3 activation and, 382–384
 JSI-124 monoclonal antibody, 384

K

Karenitecin, 411

L

Language mapping, **497–506**
 anatomic considerations in, 499–500
 imaging for, 499–501
 intraoperative, 501–503
 negative, 502
 postoperative goals of, 503–504
 Lapatinib, 383, 408
 Lenalidomide, 434
 Lithium ferrites, 442
 Lomustine, for pediatric patients, 519
 Lymphocyte-activated killer cells, 361, 460, 482–483

M

Magnetic nanoparticles, 440–444
 Magnetic resonance imaging
 for pediatric gliomas, 517–518
 functional, 500
 nanoparticles in, 440–441
 quality of life predictions from, 508
 Major vault protein, 452–455
 Manganese ferrites, 442
 Methotrexate, 521
 Microglia, defects of, 358
 Microtubule stabilizers and destabilizers, 432–433
 Monoclonal antibodies. *See also specific antibodies.*
 radiolabeled, 490
 unlabeled, 486–490
 Motexafin gadolinium, 433–434
 Multimodality immunotherapy, 362–363
 Myeloablative chemotherapy, 520

N

Nanoparticles, **439–449**
 chemotherapeutic, 442
 delivery of, 443–444
 for brachytherapy, 443
 gene delivery with, 442–443
 gold, 443
 magnetic, 440–444
 types of, 440
 vault, **451–458**
 Nanoshells, gold, 443
 Negative language mapping, 502
 Neuropsychological testing, for language function, 503
 Nickel ferrites, 442

Nimotuzumab, 490
 Nitric oxide, endothelium-derived, 399
 Nitrogen mustards, 431
 Normal tissue, protection of, in radiosensitization, 431

O

Oxygen free radicals, augmentation of, 433–434

P

p53 mutations, 516
 Paclitaxel, 433, 442
 Panitumumab, 383
 Passive immunotherapy, 360–362, **481–495**
 adoptive, 361–362, 460–462, 482–486
 antibody-mediated, 486–490
 categories of, 481–482
 Pazopanib, 409
 Pediatric patients, gliomas in, **515–523**
 clinical features of, 516–517
 epidemiology of, 515–516
 imaging of, 517–518
 in genetic syndromes, 520–521
 molecular features of, 516
 outcome of, 520
 pathology in, 516–518
 risk factors for, 515–516
 treatment of, 518–520
 Perifosine, 411
 Phosphoinositide 3-kinase, inhibitors of, 411
 Phototherapy, gold nanoparticle, 443
 Physical disability, quality of life with, 509–511
 Platelet-derived growth factor receptor
 bevacizumab effects on, 423
 inhibitors of, 409–410
 PLX4032, 520
 Protein kinase C, inhibitors of, 411
Pseudomonas exotoxin, 359–360
 Pyrazoloacridine, 411

Q

Quality of life, **507–513**
 chemotherapy considerations on, 510–511
 evaluation metrics for, 508
 hospice care and, 511–512
 multimodal molecular approach to, 512
 radiological considerations on, 508
 radiotherapy considerations on, 509–510
 surgical considerations on, 508–509

R

Radiosensitizers, **429–437**
 angiogenesis inhibitors, 432–435
 classification of, 430–431
 DNA replication inhibitors, 431–433
 microtubule stabilizers and destabilizers, 432–433

Radiosensitizers (*continued*)

redox stress augmenters, 432–434

signal pathway inhibitors, 432, 435

Radiotherapy

bevacizumab effects on, 422

for pediatric patients, 518–519

monoclonal antibodies for, 490

quality of life considerations on, 509–510

Ras signaling

in pediatric patients, 516

inhibitors of, 410–411

Recurrent glioblastoma, bevacizumab for, 418

Redox stress, augmentation of, 432–434

Resection. *See* Surgery.

Rubitecan, 411

S

Serotherapy, 360–361

Signal pathways, inhibitors of, 432, 435

Signal transducers and activators of transcription.

See STAT3 transcription factor.

Sirolimus, 411

Small molecule inhibitors, **407–416**

definition of, 408

historical review of, 407–408

of epidermal-derived growth factor receptor,
408–409

of intracellular signaling, 410–412

of platelet-derived growth factor receptor, 409–410

of vascular endothelial growth factor receptor, 410

Sorafenib, 383–384, 408, 411

Spatial cooperation, in radiosensitization, 430

STAT3 transcription factor, **379–389**

actions of, 379

in oncogenesis, 380–383

inhibitors of, 383–384

signaling pathway of, 379

Stattic, 384

Stem cells

cancer, 392, 395–396

niche for, 399

tracking of, nanoparticles for, 441

Sunitinib, 408

Superparamagnetic iron oxide-based nanoparticles,
440

Surgery

bevacizumab effects on, 421–422

for pediatric patients, 518

language mapping before, **497–506**

quality of life considerations on, 508–509

Surveillance, Epidemiology and End Results
database, 430

T

T cells

dysfunction of, 358–359

STAT3 effects on, 380–381

TALL-104 cells, 361

Tandutinib, 409

Telomerase-associated protein, 452–454

Temozolomide, 408–409, 431, 490, 498, 510, 519

Temporal modulation, in radiosensitization, 431

Temozolomide, 411

Tenascin, monoclonal antibodies to, 490

Thalidomide derivatives, 434

Thermotherapy, nanoparticles for, 441–442

Thiotepa, 520

Thromboembolism, bevacizumab and, 423

Tipifarnib, 410–411

Tirapazamine, 433

Topoisomerase inhibitors, 411–412, 431–433

Topotecan, 411

Transforming growth factor- β , 486

Tumor-derived endothelial cells, 398–399

Tumor-infiltrating lymphocytes, 361, 460–461, 483

Tyrosine kinases

inhibitors of, 435

STAT3 activation and, 382–384

U

Ubiquitin-proteasome complex inhibitors, 412

Ultrasmall superparamagnetic iron oxide-based
nanoparticles, 440

Untranslated vault RNA, 452–454

V

Vaccine(s), 362, 460–463

Vaccine for Intra-Cranial Tumor (VICTOR) study, 463

Vandetanib, 435

Vascular endothelial growth factor

bevacizumab effects on, 419–423

inhibitors of, 434–435

STAT3 effects on, 382

Vascular endothelial growth factor receptor,

inhibitors of, 410

Vatalanib, 410

Vault(s), endogenous, **451–458**Vault nanoparticles, **451–458**

Vault poly (ADP) ribose polymerase, 452–453

Venous thromboembolism, bevacizumab and, 423

Verubulin, 433

VICTOR (Vaccine for Intra-Cranial Tumor), 463

Vinca alkaloids, 433

Vincristine, for pediatric patients, 519

Vorinostat, 412

X

XL765, 520

Y

YB1 protein, 516